{"id":56073,"date":"2026-02-02T22:25:28","date_gmt":"2026-02-02T14:25:28","guid":{"rendered":"https:\/\/flcube.com\/?p=56073"},"modified":"2026-02-02T22:25:29","modified_gmt":"2026-02-02T14:25:29","slug":"vcare-pharma-partners-with-sun-novo-on-vc005-jak1-inhibitor-for-atopic-dermatitis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56073","title":{"rendered":"Vcare Pharma Partners with Sun-Novo on VC005 JAK1 Inhibitor for Atopic Dermatitis"},"content":{"rendered":"\n<p><strong>Jiangsu Vcare PharmaTech Co., Ltd.<\/strong> announced a partnership with <strong>Beijing Sun-Novo Pharmaceutical Research Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688621:SHA\">SHA: 688621<\/a>) to advance <strong>VC005 topical gel (1%)<\/strong>, a second\u2011generation highly selective <strong>JAK1 inhibitor<\/strong>, for the treatment of <strong>mild to moderate atopic dermatitis (AD)<\/strong>. Sun-Novo will receive a revenue share in mainland China and collaborate on Phase\u202fIII trials and market launch.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-structure-amp-strategic-terms\">Partnership Structure &amp; Strategic Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Companies<\/strong><\/td><td>Vcare PharmaTech \/ Sun-Novo Pharma (688621.SH)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>VC005 topical gel (1%)<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Second\u2011generation selective JAK1 inhibitor<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Mild to moderate atopic dermatitis<\/td><\/tr><tr><td><strong>Deal Structure<\/strong><\/td><td>Revenue share in mainland China + clinical collaboration<\/td><\/tr><tr><td><strong>Clinical Status<\/strong><\/td><td>Phase\u202fI &amp; II completed; Phase\u202fIII upcoming<\/td><\/tr><tr><td><strong>Potential<\/strong><\/td><td>Best\u2011in\u2011class (BIC)<\/td><\/tr><tr><td><strong>Filing History<\/strong><\/td><td>Category\u202f1 nod for clinical study (March\u202f2023)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-clinical-data\">Drug Profile &amp; Clinical Data<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Highly selective JAK1 inhibition reduces inflammatory cytokine signaling in atopic dermatitis while minimizing off\u2011target effects<\/li>\n\n\n\n<li><strong>Phase\u202fII Results:<\/strong> Demonstrated <strong>superior long\u2011term safety<\/strong>, <strong>rapid itch relief<\/strong>, and <strong>significant improvement in skin lesions<\/strong><\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Second\u2011generation selectivity may offer improved efficacy\/safety vs. first\u2011generation JAK inhibitors (tofacitinib, baricitinib)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-commercial-outlook\">Market Impact &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China Atopic Dermatitis Market:<\/strong> Valued at <strong>\u00a58\u202fbillion<\/strong> : (~US$1.1\u202fbillion) in 2025, growing at <strong>15% CAGR<\/strong> driven by biologics adoption<\/li>\n\n\n\n<li><strong>JAK Inhibitor Competition:<\/strong> Competes with <strong>Cibinqo (Pfizer)<\/strong> and <strong>Rinvoq (AbbVie)<\/strong>; VC005\u2019s topical formulation and selectivity offer convenience and safety advantages<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Analysts project <strong>\u00a51.5\u20132.5\u202fbillion<\/strong> : (US$210\u2013350\u202fmillion) peak annual sales if approved, assuming 10\u201315% market share<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> Partnership leverages Sun-Novo\u2019s regulatory expertise while Vcare retains manufacturing control; positions Vcare as a leader in next\u2011generation JAK inhibitors<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> Phase\u202fIII trial initiation expected <strong>Q2\u202f2026<\/strong>; NDA submission targeted for <strong>2028<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, regulatory pathways, and revenue projections for VC005. Actual results may differ due to clinical trial outcomes, competitive dynamics, and NMPA review processes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Vcare PharmaTech Co., Ltd. announced a partnership with Beijing Sun-Novo Pharmaceutical Research Co., Ltd&#8230;.<\/p>\n","protected":false},"author":1,"featured_media":56075,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[65,1262,2604,573],"class_list":["post-56073","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-auto-immune","tag-sha-688621","tag-sun-novo-pharmaceutical-research","tag-vcare-pharmatech"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Vcare Pharma Partners with Sun-Novo on VC005 JAK1 Inhibitor for Atopic Dermatitis - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Vcare PharmaTech Co., Ltd. announced a partnership with Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA: 688621) to advance VC005 topical gel (1%), a second\u2011generation highly selective JAK1 inhibitor, for the treatment of mild to moderate atopic dermatitis (AD). Sun-Novo will receive a revenue share in mainland China and collaborate on Phase\u202fIII trials and market launch.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56073\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vcare Pharma Partners with Sun-Novo on VC005 JAK1 Inhibitor for Atopic Dermatitis\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Vcare PharmaTech Co., Ltd. announced a partnership with Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA: 688621) to advance VC005 topical gel (1%), a second\u2011generation highly selective JAK1 inhibitor, for the treatment of mild to moderate atopic dermatitis (AD). Sun-Novo will receive a revenue share in mainland China and collaborate on Phase\u202fIII trials and market launch.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56073\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-02T14:25:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-02T14:25:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0212.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56073#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56073\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Vcare Pharma Partners with Sun-Novo on VC005 JAK1 Inhibitor for Atopic Dermatitis\",\"datePublished\":\"2026-02-02T14:25:28+00:00\",\"dateModified\":\"2026-02-02T14:25:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56073\"},\"wordCount\":317,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56073#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0212.webp\",\"keywords\":[\"Auto-immune\",\"SHA: 688621\",\"Sun-Novo Pharmaceutical Research\",\"Vcare PharmaTech\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56073#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56073\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56073\",\"name\":\"Vcare Pharma Partners with Sun-Novo on VC005 JAK1 Inhibitor for Atopic Dermatitis - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56073#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56073#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0212.webp\",\"datePublished\":\"2026-02-02T14:25:28+00:00\",\"dateModified\":\"2026-02-02T14:25:29+00:00\",\"description\":\"Jiangsu Vcare PharmaTech Co., Ltd. announced a partnership with Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA: 688621) to advance VC005 topical gel (1%), a second\u2011generation highly selective JAK1 inhibitor, for the treatment of mild to moderate atopic dermatitis (AD). Sun-Novo will receive a revenue share in mainland China and collaborate on Phase\u202fIII trials and market launch.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56073#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56073\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56073#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0212.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0212.webp\",\"width\":1080,\"height\":608,\"caption\":\"Vcare Pharma Partners with Sun-Novo on VC005 JAK1 Inhibitor for Atopic Dermatitis\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56073#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vcare Pharma Partners with Sun-Novo on VC005 JAK1 Inhibitor for Atopic Dermatitis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Vcare Pharma Partners with Sun-Novo on VC005 JAK1 Inhibitor for Atopic Dermatitis - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Vcare PharmaTech Co., Ltd. announced a partnership with Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA: 688621) to advance VC005 topical gel (1%), a second\u2011generation highly selective JAK1 inhibitor, for the treatment of mild to moderate atopic dermatitis (AD). Sun-Novo will receive a revenue share in mainland China and collaborate on Phase\u202fIII trials and market launch.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56073","og_locale":"en_US","og_type":"article","og_title":"Vcare Pharma Partners with Sun-Novo on VC005 JAK1 Inhibitor for Atopic Dermatitis","og_description":"Jiangsu Vcare PharmaTech Co., Ltd. announced a partnership with Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA: 688621) to advance VC005 topical gel (1%), a second\u2011generation highly selective JAK1 inhibitor, for the treatment of mild to moderate atopic dermatitis (AD). Sun-Novo will receive a revenue share in mainland China and collaborate on Phase\u202fIII trials and market launch.","og_url":"https:\/\/flcube.com\/?p=56073","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-02T14:25:28+00:00","article_modified_time":"2026-02-02T14:25:29+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0212.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56073#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56073"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Vcare Pharma Partners with Sun-Novo on VC005 JAK1 Inhibitor for Atopic Dermatitis","datePublished":"2026-02-02T14:25:28+00:00","dateModified":"2026-02-02T14:25:29+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56073"},"wordCount":317,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=56073#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0212.webp","keywords":["Auto-immune","SHA: 688621","Sun-Novo Pharmaceutical Research","Vcare PharmaTech"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56073#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56073","url":"https:\/\/flcube.com\/?p=56073","name":"Vcare Pharma Partners with Sun-Novo on VC005 JAK1 Inhibitor for Atopic Dermatitis - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=56073#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=56073#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0212.webp","datePublished":"2026-02-02T14:25:28+00:00","dateModified":"2026-02-02T14:25:29+00:00","description":"Jiangsu Vcare PharmaTech Co., Ltd. announced a partnership with Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA: 688621) to advance VC005 topical gel (1%), a second\u2011generation highly selective JAK1 inhibitor, for the treatment of mild to moderate atopic dermatitis (AD). Sun-Novo will receive a revenue share in mainland China and collaborate on Phase\u202fIII trials and market launch.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56073#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56073"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=56073#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0212.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0212.webp","width":1080,"height":608,"caption":"Vcare Pharma Partners with Sun-Novo on VC005 JAK1 Inhibitor for Atopic Dermatitis"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56073#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Vcare Pharma Partners with Sun-Novo on VC005 JAK1 Inhibitor for Atopic Dermatitis"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0212.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56073","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56073"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56073\/revisions"}],"predecessor-version":[{"id":56076,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56073\/revisions\/56076"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/56075"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56073"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56073"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56073"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}